Hims & Hers Health has staged a sharp reversal this week — up 16% to $31.75 — flipping the script on a note filed just days ago that described extreme hedging demand and relentless selling pressure.
The positioning picture has shifted in a way that makes this rally more than just a bounce. Short interest has declined steadily through the week, falling nearly 5% to 26.4% of the free float — still elevated, but moving in the right direction for longs. That's a meaningful change from the prior note, where SI was essentially flat around 60-61 million shares; it's now tracking closer to 58 million. The borrow market has loosened considerably alongside the price move: availability has risen to 62%, up from around 53% a week ago, and cost to borrow has dropped 26% on the week to just 0.66% — its lowest level in roughly six weeks. Tighter shorts, looser borrow, cheaper cost to borrow: the setup that previously looked like a coiled spring for further downside now reads more like short covering than fresh conviction. Options have moved with the stock. The put/call ratio jumped to 0.63 on Tuesday — nearly 2.7 standard deviations above its 20-day average of 0.58 — but that reading now sits at the upper end of recent norms rather than the historic extreme seen last week above three standard deviations. The hedging urgency has eased.
The Street is sending a similarly mixed but less hostile message. After the August 10 earnings print, analysts almost universally raised targets while maintaining cautious ratings — a pattern that kept the stock under pressure through mid-month. This week, Truist nudged its target to $32 (from $27), while Barclays trimmed to $35 from $39, keeping Overweight. The consensus mean target is $31.23, which is essentially where the stock closed — meaning the Street as a whole has little implied upside left at current prices, even after the rally. Morgan Stanley sits at Equal-Weight with a $28 target; BofA at Neutral and $32. Bulls point to a proven digital platform, strong subscriber retention, and a GLP-1 expansion story that remains in early innings. Bears focus on the competitive threat from healthcare giants and venture-backed rivals crowding the weight-loss drug market, plus the regulatory overhang that comes with operating at the edge of pharmaceutical compounding rules. EPS momentum ranks in the bottom 15th percentile of the universe, and the EPS surprise factor score is near the floor at the 2nd percentile — the most recent earnings reaction confirmed that wariness, with the stock falling 3.4% the day after results and extending losses to nearly 9.5% over the following five days.
Institutional ownership adds one more layer of context. FMR added over 4.2 million shares in the most recent reporting period, and Goldman Sachs added 2.4 million — both meaningful additions. Divisadero Street Capital built a near-5.5 million share position from a standing start. At the same time, the founder and CEO Andrew Dudum sold $2.2 million of stock on August 14, joined by the CFO and Chief Legal Officer with smaller sells across August 17-19. These insider sales followed restricted stock awards, which tempers their signal somewhat, but the cluster of executive selling into the first post-earnings bounce is worth noting alongside the institutional buying.
The ORTEX short score sits at 70.5 — elevated, reflecting the structural weight of a 26% short float and high borrow demand relative to history — but it has drifted down slightly through the week from 71.1, consistent with the modest short covering visible in the daily estimates. With the next earnings event not until November 2, the question over the coming weeks is whether the short covering continues to fuel the rally or whether sellers regroup as the stock approaches — and now exceeds — the Street's consensus target.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
